title: Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
abstract: BACKGROUND
  Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the effect of purging is unknown. We did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma.
  
  
  METHODS
  Between March 16, 2001, and Feb 24, 2006, children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis by a web-based system (in a 1:1 ratio) to receive either non-purged or immunomagnetically purged PBSC. Randomisation was done in blocks stratified by International Neuroblastoma Staging System stage, age, MYCN status, and International Neuroblastoma Pathology classification. Patients and treating physicians were not masked to treatment assignment. All patients were treated with six cycles of induction chemotherapy, myeloablative consolidation, and radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy, followed by oral isotretinoin. PBSC collection was done after two induction cycles. For purging, PBSC were mixed with carbonyl iron and phagocytic cells removed with samarium cobalt magnets. Remaining cells were mixed with immunomagnetic beads prepared with five monoclonal antibodies targeting neuroblastoma cell surface antigens and attached cells were removed using samarium cobalt magnets. Patients underwent autologous stem-cell transplantation with PBSC as randomly assigned after six cycles of induction therapy. The primary endpoint was event-free survival and was analysed by intention-to-treat. The trial is registered with ClinicalTrials.gov, number NCT00004188.
  
  
  RESULTS
  495 patients were enrolled, of whom 486 were randomly assigned to treatment: 243 patients to receive non-purged PBSC and 243 to received purged PBSC. PBSC were collected from 229 patients from the purged group and 236 patients from the non-purged group, and 180 patients from the purged group and 192 from the non-purged group received transplant. 5-year event-free survival was 40% (95% CI 33-46) in the purged group versus 36% (30-42) in the non-purged group (p=0·77); 5-year overall survival was 50% (95% CI 43-56) in the purged group compared with 51% (44-57) in the non-purged group (p=0·81). Toxic deaths occurred in 15 patients during induction (eight in the purged group and seven in the non-purged group) and 12 during consolidation (eight in the purged group and four in the non-purged group). The most common adverse event reported was grade 3 or worse stomatitis during both induction (87 of 242 patients in the purged group and 93 of 243 patients in the non-purged group) and consolidation (131 of 177 in the purged group vs 145 of 191 in the non-purged group). Serious adverse events during induction were grade 3 or higher decreased cardiac function (four of 242 in the purged group and five of 243 in the non-purged group) and elevated creatinine (five of 242 in the purged group and six of 243 non-purged group) and during consolidation were sinusoidal obstructive syndrome (12 of 177 in the purged group and 17 of 191 in the non-purged group), acute vascular leak (11 of 177 in the purged group and nine of 191 in the non-purged group), and decreased cardiac function (one of 177 in the purged group and four of 191 in the non-purged group).
  
  
  CONCLUSIONS
  Immunomagnetic purging of PBSC for autologous stem-cell transplantation did not improve outcome, perhaps because of incomplete purging or residual tumour in patients. Non-purged PBSC are acceptable for support of myeloablative therapy of high-risk neuroblastoma.
authors.affiliation: Duke University Medical Center, Durham, NC, USA. susan.kreissman@duke.edu
authors.forename: Susan G
authors.initials: SG
authors.lastname: Kreissman
authors.forename: Robert C
authors.initials: RC
authors.lastname: Seeger
authors.forename: Katherine K
authors.initials: KK
authors.lastname: Matthay
authors.forename: Wendy B
authors.initials: WB
authors.lastname: London
authors.forename: Richard
authors.initials: R
authors.lastname: Sposto
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
authors.forename: Daphne A
authors.initials: DA
authors.lastname: Haas-Kogan
authors.forename: Michael P
authors.initials: MP
authors.lastname: Laquaglia
authors.forename: Alice L
authors.initials: AL
authors.lastname: Yu
authors.forename: Lisa
authors.initials: L
authors.lastname: Diller
authors.forename: Allen
authors.initials: A
authors.lastname: Buxton
authors.forename: Julie R
authors.initials: JR
authors.lastname: Park
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
authors.forename: John M
authors.initials: JM
authors.lastname: Maris
authors.forename: C Patrick
authors.initials: CP
authors.lastname: Reynolds
authors.forename: Judith G
authors.initials: JG
authors.lastname: Villablanca
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D006801:Humans; D018189:Immunomagnetic Separation; D007223:Infant; D009447:Neuroblastoma / Q000401:mortality / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D012306:Risk
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5680-5
references.pmid: 17020970
references.citation: J Clin Oncol. 2003 Oct 15;21(20):3853-8
references.pmid: 14551304
references.citation: J Clin Oncol. 2005 Jan 20;23(3):532-40
references.pmid: 15659499
references.citation: Bone Marrow Transplant. 2013 Jul;48(7):947-52
references.pmid: 23334272
references.citation: Haematologica. 2007 Aug;92(8):1083-90
references.pmid: 17640853
references.citation: Cancer Res. 1986 Nov;46(11):5878-81
references.pmid: 2428486
references.citation: Control Clin Trials. 1984 Dec;5(4):348-61
references.pmid: 6518769
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1007-13
references.pmid: 19171716
references.citation: J Clin Oncol. 2000 Dec 15;18(24):4067-76
references.pmid: 11118468
references.citation: J Clin Oncol. 1993 Aug;11(8):1466-77
references.pmid: 8336186
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: N Engl J Med. 2010 Jun 10;362(23):2202-11
references.pmid: 20558371
references.citation: Pediatr Blood Cancer. 2007 Sep;49(3):234-9
references.pmid: 17252561
references.citation: Pediatr Blood Cancer. 2010 Apr;54(4):596-602
references.pmid: 20049927
references.citation: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1424-31
references.pmid: 16427213
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6459-65
references.pmid: 16116153
references.citation: Blood. 1994 Jul 15;84(2):380-3
references.pmid: 8025266
references.citation: J Clin Oncol. 2004 Dec 15;22(24):4888-92
references.pmid: 15611504
references.citation: Cancer. 1999 Jul 15;86(2):364-72
references.pmid: 10421273
references.citation: Pediatr Blood Cancer. 2013 Sep;60(9):E109-12
references.pmid: 23596146
references.citation: Med Pediatr Oncol. 2001 Jan;36(1):213-9
references.pmid: 11464888
references.citation: Cancer Res. 1986 Nov;46(11):5882-6
references.pmid: 3756928
references.citation: N Engl J Med. 2010 Sep 30;363(14):1324-34
references.pmid: 20879881
references.citation: Eur J Cancer. 2011 May;47(8):1193-202
references.pmid: 21429738
references.citation: Br J Cancer. 2009 May 19;100(10):1627-37
references.pmid: 19401690
references.citation: Cancer Res. 1986 Jan;46(1):440-3
references.pmid: 3940209